Douglas Kerr
Head of Research & Development and Chief Medical OfficerDr. Douglas Kerr, M.D. Ph.D. MBA, also known as Doug, is a Director at GenrAb, Inc. He is Director of Trace Neuroscience, Inc. Dr. Kerr is a Science Advisor at Exceptional Ventures LLP. He is Chief Medical Officer of Dyne Therapeutics, Inc. since September 03, 2024 and serves as Head of Research & Development since October 202. He serves as an Advisor at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2017. Dr. Kerr was Chief Medical Officer at Generation Bio Co. since November 2020 until January 28, 2024. He has been Director of Faze Medicines since May 2021. He served as Chief Development Officer of Generation Bio Co. since May 2019 until November 2020 and served as its Head of Preclinical Research & Clinical Development. Previously, Dr. Kerr served as chief scientific officer and executive vice president of research and development at Generation Bio Co. from August 2017 to May 2019. Dr. Kerr joined Generation Bio in 2017 at Generation Bio Co. Dr. Kerr has been Scientific Advisor of Grace 2, Inc. since October 13, 2011. Dr. Kerr serves as a Scientific Advisor of Q Therapeutics, Inc. Dr. Kerr serves as Medical Director of Neurology Research and Development at Biogen Idec, where Dr. Kerr is responsible for late-stage neurodegenerative programs, focusing on motor neuron disorders ALS and SMA. Dr. Kerr is an expert in autoimmune neurodegenerative diseases such as Multiple Sclerosis and Transverse Myelitis. Dr. Kerr established the world leading Transverse Myelitis center at Johns Hopkins Medical School. Dr. Kerr is an Associate Professor of Neurology with joint appointments in the Department of Molecular Microbiology and Immunology and Cellular and Molecular Medicine at Johns Hopkins University. He specializes in transverse myelitis and multiple sclerosis. Dr. Kerr also works on stem cells as a therapeutic tool for functional recovery in patients with TM and motor neuron diseases and the Principal Investigator for the Company's Phase I/IIa Clinical Trial in Transverse Myelitis. Dr. Kerr is also conducting preclinical studies with Q Therapeutics. Dr. Kerr has established the Johns Hopkins Transverse Myelitis Center which is the only such center in the entire world. Dr. Kerr has research interests in determining the cause(s) of transverse myelitis, evaluating novel markers to help prognosticate outcomes in the acute phase and in developing novel treatments. Dr. Kerr also investigates neural stem cells as a potential tool for functional recovery in patients with transverse myelitis and motor neuron disease. He has made significant discoveries concerning the basic molecular biology of neuronal apoptosis, especially in motor neurons of the spinal cord. Dr. Kerr's laboratory research focuses on models of neuronal injury in the spinal cord. Using genetic and viral induced models of motoneuron injury, his laboratory has found that though there is an intrinsic abnormality within neurons, this abnormality is insufficient to induce death of that neuron. His research laboratory is focused on elucidating the pathways involved in this phenomenon. These findings are relevant to viral induced diseases of the CNS and to human motor neuron diseases such as ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). Dr. Kerr also directs The Johns Hopkins Project RESTORE, a multidisciplinary research and clinical collaboration emerging from The Johns Hopkins Transverse Myelitis and Multiple Sclerosis Centers to develop new diagnostic and therapeutic strategies in the treatment of neuroimmunologic disorders, such as multiple sclerosis (MS) and transverse myelitis (TM). Project RESTORE has three principal goals: to recover from acute attacks and illness; to stop progression of disease and disability; and to regenerate nerve cells and myelin. Dr. Kerr has also been interested in the endogenous response of spinal cord neural stem cells to paralysis. Dr. Kerr served as Member of Scientific Advisory Board of California Stem Cell, Inc. Dr. Kerr served as global development team lead and vice president for neurology at Shire plc from October 2015 to August 2017 where he was responsible for the development of the rare neuroscience programs including the lysosomal storage disorders, neurodegeneration and gene therapy candidates. He serves as Director of Triplet Therapeutics, Inc since July 2019, BlueRock Therapeutics LP and Faze Medicines, Inc. a biotechnology company, since May 2021. He served as senior director of corporate strategy and portfolio management at Biogen, where he led the development effort for Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Dr. Kerr earned a B.A. degree in biochemistry from Princeton University. Dr. Kerr obtained his Master of Business Administration, with a specialization in entrepreneurship and finance from Northeastern University, as well as his Bachelor of Science degree in molecular biology from Princeton University and an M.D. from Jefferson Medical College, as well as a doctorate in biochemistry and molecular biology.
Positions
- Company NameDyne Therapeutics, Inc.Stock CodeDYNPositionHead of Research & Development and Chief Medical OfficerColleagues
- JGJohn G. CoxCEO, President & Director
- JPJason P. RhodesIndependent Chairman
- EJErick J. LuceraCFO, Principal Financial Officer & Principal Accounting Officer and Treasurer
- OBOxana BeskrovnayaChief Innovation Officer
- JFJohanna Friedl-NadererChief Commercial Officer
- DKDirk KerstenIndependent Director
- DCDavid Charles LubnerIndependent Director
- EMEdward M. HurwitzIndependent Director
